EBS Emergent BioSolutions (EBS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001367644
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
100
13F, latest reported quarter
What the filings say about EBS
Insiders, 180 days
-$561.0K net sold
4 sellers · 22% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2024-12-11
Planned sales (Form 144), 90 days
$145.7K
2 notices
Emergent BioSolutions insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Emergent BioSolutions Inc. insiders sold a net $561.0K of stock across 33 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on May 1, 2026.
- The trade is 15.9% of the 111,921 shares held after it.
- 1 other insider sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DeGolyer Donald W sold about $126.2K of EBS under a 10b5-1 plan on Oct 7, 2026; 1 other insider sold within 30 days and 100 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jul 1, 2026.
- The trade is 1.9% of the 156,098 shares held after it.
- 1 other insider sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Products Business Williams Paul Anthony sold about $19.6K of EBS under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 100 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 1, 2026.
- The trade is 1.9% of the 159,098 shares held after it.
- No other insider sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Products Business Williams Paul Anthony sold about $25.2K of EBS on Jul 1, 2026; 100 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 7, 2025.
- The trade is 1.0% of the 100,563 shares held after it.
- 4 other insiders sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dayal Sujata Tyagi sold about $8.8K of EBS on May 1, 2026; 4 other insiders sold within 30 days and 100 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 7, 2025.
- The trade is 12.6% of the 101,543 shares held after it.
- 4 other insiders sold within 30 days.
- 100 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dayal Sujata Tyagi sold about $106.8K of EBS on May 1, 2026; 4 other insiders sold within 30 days and 100 funds added in the latest 13F quarter.33 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$561.0K over 180 days
-$145.8K over 90 days
below 57% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
100 funds bought in last quarter
more than 68% of Pharma & Biotech
Revenue
-28.8% year over year
below 72% of Pharma & Biotech
Margin
7.1% net margin
more than 79% of Pharma & Biotech
Buybacks
$18.0M repurchased, FY to 2026-06-30
below 62% of Pharma & Biotech
Short interest
19.7% of the float short (float per yahoo 2026-10-27) · 9.0 days to cover · settled 2026-10-15
more than 92% of Pharma & Biotech
What changed in the last 30 days
Oct 7Director DeGolyer Donald W sold $126.2K under a 10b5-1 plan (Oct 7)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 7Director DONALD DEGOLYER filed to sell $126.1K by Oct 7 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 5SVP, Products Business Williams Paul Anthony sold $19.6K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Officer PAUL WILLIAMS filed to sell $19.6K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch EBS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-34.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns EBS: institutional holders (13F)
13F holdings, latest reported quarter
4,716,599 sh
$39.5M
3,076,646 sh
$25.8M
2,929,238 sh
$24.6M
2,770,448 sh
$23.2M
2,198,839 sh
$18.4M
Congress trades in EBS
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2024-12-11 · disclosed 30 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
EBS planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
DONALD DEGOLYER
Filed 2026-10-07
$126.1K
PAUL WILLIAMS
Filed 2026-10-01
$19.6K
PAUL WILLIAMS
Filed 2026-07-01
$25.2K
EBS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
FULLERTHALER BEHAVIORAL MICRO-CAP EQUITY FUND
$688.5K position · as of 2026-06-30
2.3%
Ancora/Thelen Small-Mid Cap Fund
$2.8M position · as of 2026-06-30
1.2%
Cambria Micro and SmallCap Shareholder Yield ETF
$296.4K position · as of 2026-07-31
0.9%
JAMES SMALL CAP FUND
$414.7K position · as of 2026-06-30
0.5%
JAMES MICRO CAP FUND
$102.0K position · as of 2026-06-30
0.3%
Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value Fund
$500.9K position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
47 registered trials, 7 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
18
Phase 1
0 active
8
Phase 2
0 active
4
Phase 3
0 active
4
Phase 4
2 active
11
Not applicable
5 active
2
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
IGF::OT::IGF · 2016-09-30
$1.4B
Department Of Health And Human Services
ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) · 2019-08-30
$857.6M
Department Of Health And Human Services
BOTULISM ANTITOXIN · 2019-09-30
$320.9M
Department Of Health And Human Services
CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL · 2022-08-29
$213.8M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Emergent Biosolutions Inc. Employees Pac
Cycle 2026 · $50K spent
$49.6K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Mr. Kramer
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.3M
$9.4M
$1.8M
-86%
+71%
2022
$7.6M
$508.3K
$3.4M
-78%
+41%
2021
$6.9M
$532.4K
$2.5M
-19%
+22%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $561.0K sold by insiders over 180 days, 100 funds added last quarter, $145.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
EBS financials
Revenue growth
-28.8%
XBRL, annual
Net margin
7.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$770.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM EBS
| FY Dec 2025 | $742.9M |
| FY Dec 2024 | $1.0B |
| FY Dec 2023 | $1.1B |
| FY Dec 2022 | $1.1B |
| FY Dec 2021 | n/a |
| Jun 2026 | $234.3M |
| Mar 2026 | $156.1M |
| Dec 2025 | $148.7M |
| Sep 2025 | $231.1M |
| Jun 2025 | $140.9M |
| Mar 2025 | $222.2M |
| Dec 2024 | $194.7M |
| Sep 2024 | $293.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-23.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM EBS
| FY Dec 2025 | +7.1% |
| FY Dec 2024 | -18.3% |
| FY Dec 2023 | -72.4% |
| FY Dec 2022 | -18.9% |
| FY Dec 2021 | n/a |
| Jun 2026 | -76.9% |
| Mar 2026 | +4.4% |
| Dec 2025 | -36.7% |
| Sep 2025 | +22.2% |
| Jun 2025 | -8.5% |
| Mar 2025 | +30.6% |
| Dec 2024 | -16.1% |
| Sep 2024 | +39.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$85.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM EBS
| FY Dec 2025 | $156.8M |
| FY Dec 2024 | $35.8M |
| FY Dec 2023 | -$257.9M |
| FY Dec 2022 | -$149.9M |
| FY Dec 2021 | $96.1M |
| Jun 2026 | $54.0M |
| Mar 2026 | -$36.2M |
| Dec 2025 | $73.8M |
| Sep 2025 | -$5.7M |
| Jun 2025 | $103.5M |
| Mar 2025 | -$14.8M |
| Dec 2024 | -$81.6M |
| Sep 2024 | $147.9M |
At each fiscal year end
Single quarter
Debt to equity
1.70x
long-term 2026-06-30 plus current 2024-12-31 (18 months older than the period end); equity 2026-06-30
Debt to equity EBS
| FY Dec 2025 | 1.09x |
| FY Dec 2024 | 1.37x |
| FY Dec 2023 | 1.32x |
| FY Dec 2022 | 1.01x |
| FY Dec 2021 | 0.52x |
| Jun 2026 | 1.70x |
| Mar 2026 | 1.10x |
| Dec 2025 | 1.09x |
| Sep 2025 | 1.14x |
| Jun 2025 | 1.25x |
| Mar 2025 | 1.20x |
| Dec 2024 | 1.37x |
| Sep 2024 | 1.30x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.17x
TTM operating cash flow over long-term 2026-06-30 plus current 2024-12-31 (18 months older than the period end)
Cash flow to debt EBS
| FY Dec 2025 | 0.30x |
| FY Dec 2024 | 0.09x |
| FY Dec 2023 | -0.24x |
| FY Dec 2022 | -0.02x |
| FY Dec 2021 | 0.38x |
| Jun 2026 | 0.17x |
| Mar 2026 | 0.26x |
| Dec 2025 | 0.30x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.25x |
| Mar 2025 | 0.17x |
| Dec 2024 | 0.09x |
| Sep 2024 | 0.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-40.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity EBS
| FY Dec 2025 | +10.5% |
| FY Dec 2024 | -33.7% |
| FY Dec 2023 | -74.7% |
| FY Dec 2022 | -14.1% |
| FY Dec 2021 | +14.3% |
| Jun 2026 | -40.3% |
| Mar 2026 | -1.6% |
| Dec 2025 | +10.5% |
| Sep 2025 | +13.9% |
| Jun 2025 | +30.2% |
| Mar 2025 | -21.6% |
| Dec 2024 | -33.7% |
| Sep 2024 | -34.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-14.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets EBS
| FY Dec 2025 | +3.9% |
| FY Dec 2024 | -11.9% |
| FY Dec 2023 | -30.5% |
| FY Dec 2022 | -6.9% |
| FY Dec 2021 | +7.5% |
| Jun 2026 | -14.0% |
| Mar 2026 | -0.6% |
| Dec 2025 | +3.9% |
| Sep 2025 | +5.2% |
| Jun 2025 | +9.5% |
| Mar 2025 | -8.1% |
| Dec 2024 | -11.9% |
| Sep 2024 | -12.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital EBS
| FY Dec 2025 | +6.9% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +13.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | +6.9% |
| Sep 2025 | +8.4% |
| Jun 2025 | +8.1% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-5.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed EBS
| FY Dec 2025 | +8.3% |
| FY Dec 2024 | -9.1% |
| FY Dec 2023 | -46.7% |
| FY Dec 2022 | -7.5% |
| FY Dec 2021 | +13.4% |
| Jun 2026 | -5.8% |
| Mar 2026 | +4.9% |
| Dec 2025 | +8.3% |
| Sep 2025 | +9.2% |
| Jun 2025 | +9.8% |
| Mar 2025 | -7.9% |
| Dec 2024 | -9.1% |
| Sep 2024 | -11.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing EBS
| FY Dec 2025 | 13.43x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 10.68x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 13.43x |
| Sep 2025 | 6.73x |
| Jun 2025 | 2.59x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$767.2M
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2024-12-31 (18 months older than the period end), minus cash 2026-06-30
Enterprise value EBS
| FY Dec 2025 | $1.0B |
| FY Dec 2024 | $1.1B |
| FY Dec 2023 | $873.0M |
| FY Dec 2022 | $1.4B |
| FY Dec 2021 | $2.6B |
| Jun 2026 | $874.5M |
| Mar 2026 | $843.0M |
| Dec 2025 | $1.0B |
| Sep 2025 | $888.2M |
| Jun 2025 | $746.8M |
| Mar 2025 | $780.7M |
| Dec 2024 | $1.1B |
| Sep 2024 | $954.5M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+26.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield EBS
| FY Dec 2025 | +24.2% |
| FY Dec 2024 | +6.9% |
| FY Dec 2023 | -207.1% |
| FY Dec 2022 | -25.4% |
| FY Dec 2021 | +4.1% |
| Jun 2026 | +19.9% |
| Mar 2026 | +31.5% |
| Dec 2025 | +24.2% |
| Sep 2025 | +0.3% |
| Jun 2025 | +44.8% |
| Mar 2025 | +35.7% |
| Dec 2024 | +6.9% |
| Sep 2024 | +31.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing EBS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $742.9M | $1.0B | $1.0B | $1.1B |
| Gross profit | n/a | n/a | $317.6M | $383.0M |
| Operating income | $100.1M | -$108.7M | -$726.4M | -$170.0M |
| Net income | $52.6M | -$190.6M | -$760.5M | -$211.6M |
| EPS (diluted) | 0.93 | -3.60 | -14.85 | -4.22 |
| Operating cash flow | $170.6M | $58.7M | -$206.3M | -$34.1M |
| Cash | $205.4M | $99.5M | $111.7M | $642.6M |
| Long-term debt | $572.1M | $663.7M | $446.5M | $448.5M |
| Buybacks | $24.9M | $0 | $0 | $82.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
EBS Stock Sonar score 6/7 axes
Find similar shapesCompareEBS ranks highest on institutional and government (78th percentile) and profitability (71st), and lowest on insider conviction (21st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
EBS filings, in plain words
Are Emergent BioSolutions insiders buying or selling EBS?
In the 180 days to 2026-10-28, Emergent BioSolutions insiders were net sellers, a net $561.0K across purchases and sales reported on Form 4, by 4 sellers.
Have members of Congress traded EBS?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Steve Cohen dated 2024-12-11.
Are there planned insider sales of EBS?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $145.7K of stock; the latest, by DONALD DEGOLYER, was filed 2026-10-07.
Read the full summary
In the 180 days to 2026-10-28, Emergent BioSolutions insiders were net sellers of EBS, a net $561.0K across purchases and sales reported on Form 4 by 4 sellers. 22% of the 9 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in EBS, none in the last year; the latest on record is a sale by Steve Cohen dated 2024-12-11. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $145.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
